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Abstract A series of palladium(II) (1–3) and plat-
inum(II) chloride complexes (4 and 5) with 2,20:60,200-
terpyridine (terpy) derivatives substituted at the 40
position, was synthesized and fully characterized.
Single crystal X-ray diffraction analysis of complexes
2, 3 and 5 showed tridentate coordination of the 40-
substituted terpyridine (terpy) ligands to the metal
center. Moreover, in vitro cytotoxic activity of these
complexes toward a panel of human cancer cell lines
(lung cancer A549, colorectal cancer HCT116,
ovarian cancer IGROV-1) and toward normal cell
line HDF (dermal fibroblast) was determined by
Trypan Blue exclusion assay. Overall, the tested
compounds manifested a relevant cytotoxicity for
the selected cancer cell lines with complex 4 also
showing a modest cytotoxicity on the normal cell
lines. To better understand the mode of action of these
metal complexes, their reactivity with three model
proteins, i.e. hen egg white lysozyme (HEWL),
cytochrome c (cyt c) and ribonuclease A (RNase A)
were comparatively investigated through ESI–MS
analysis. The results highlighted a different behavior
between the two series of complexes being platinum
compounds more reactive toward RNase and cyt c
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than palladium compounds. Based on the obtained
results, it is proposed that in presence of RNase A and
cyt c, the platinum complexes undergo activation
through release of labile ligands followed by binding
to the protein. In contrast, palladium complexes
revealed a far lower reactivity implying the likely
occurrence of a different mechanism of action.
Keywords Platinum and palladium complexes 
Single crystal X-ray diffraction analysis  Anticancer
drugs  Interactions with biomolecules
Introduction
Since the discovery of the anticancer properties of
cisplatin, carboplatin and oxaliplatin, metal-based
drugs have been recognized as very promising agents
capable of revolutionizing cancer therapy (Jakupec
et al. 2008; Quiroga 2012; Muggia 2009; Jamieson and
Lippard 1999). Following the success of these com-
pounds, a large number of structurally similar com-
pounds have been synthesized in the attempt to
discover more effective anti-tumor drugs. During the
last two decades, several non-platinum complexes
based on ruthenium, gold, palladium or titanium with
structures that are not directly related to platinum-
based drugs have been evaluated as potential anti-
cancer drugs (Cutillas et al. 2013; Gasser et al. 2011).
Furthermore, significant antitumor activity with a
lower systemic toxicity than cisplatin has been
described in the literature for several palladium(II)
complexes (Rocha et al. 2010; Gao et al. 2010;
Trevisan et al. 2002). Coordination chemistry of
polypyridyl ligands attracts widespread interest based
on the wide range of applications for the resulting
metal complexes. In the field of biology and medicine
these complexes are particularly investigated as pho-
tocleavage agents for DNA, as complexes with
promising cytotoxic effect and for their luminescence
properties (Indumathy et al. 2007; Zhang et al. 2001).
Among them, complexes with general formula
[M(terpy)2]
n? or [M(terpy)Xm]
n? (where M = a d-
block element, such as ruthenium(II) or osmium(II),
terpy = terpyridine, (un)substituted 2,6-bis(2-pyri-
dyl)pyridine and X = halide/pseudo halide) are very
interesting for their electrochemical, catalytic and
optical properties (Naseri et al. 2012; Yeung et al.
2010; Sauvage et al. 1994). Terpy and its derivatives
are well-established ligands for transition metals,
especially those with d8 configuration, which form
square-planar complexes (Hollis and Lippard 1983;
Jennette et al. 1976; Lippard 1978). Thus, it is not
surprising that medicinal and bioinorganic chemistry
of Pt(II) and Pd(II) complexes with (un)substituted
terpy represent a field of wide interest (Eryazici et al.
2008). The complexes [PdCl(terpy)](sac)2H2O and
[Pd(sac)(terpy)](sac)4H2O (sac = saccharinate)
(Fig. 1, compound a) showed strong anti-cancer
activity against breast cancer cells, inducing apopto-
sis. Moreover, these complexes are able to signifi-
cantly reduce tumor growth in vivo (Ulukaya et al.
2011). The introduction of structural modification on
the terpy molecule, especially at the 40 position,
generates various substituted terpy ligands, affecting
the antitumor activity of the resulting complexes
(Kumar et al. 2011; Patel et al. 2012; Ma et al. 2010;
Shi et al. 2006; Chu et al. 2013). It has also been shown
that the substituent in the 40 position plays an
important role in increasing the solubility of the
complex and the interaction with DNA (Chu et al.
2013). Pt(II), Pd(II), Zn(II) and Cu(II) complexes with
40-substituted terpy exhibited promising cytotoxicity
against several cell lines, with IC50 values comparable
or even lower than cisplatin (Fig. 1, compounds b, c, d
and e) (Wang et al. 2013). The development of new
selective and sensitive bioanalytical techniques
allowed to better understand the mode of action of
metal-based drugs. It is common opinion that the
primary target for the pharmacological effects of
cisplatin is nuclear DNA. Thus, cisplatin exerts its
cytotoxicity through binding of the Pt(II) center at the
level of the N7 atom of adjacent guanines, resulting in
1,2 and 1,3-intrastrand or interstrand cross-links (Todd
and Lippard 2010). The binding inhibits DNA repli-
cation finally leading to apoptosis (Wang and Lippard
2005). However, in the last decades, a number of
studies have shown that metal-based drugs undergo a
wide range of biomolecular interactions, with proteins
being possible targets for binding too. In this view, the
mode of action of ruthenium and gold compounds are
still unknown and are a matter of intense research and
debate. It has been reported that for some of these
compounds the favored target are the proteins instead
of DNA (Gasser et al. 2011; Gabbiani et al. 2012),
protein metalation being the process through which
proteins are modified with metal species (often a
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molecular fragment derived from the starting metal
complex).
The metallic fragments may interact with the
proteins by a direct coordinative bond or through a
non-covalent interaction, resulting in the formation of
adducts between the protein and a metal species
(Gabbiani et al. 2011). Detailed characterization of the
resulting metal-protein adducts, including identifica-
tion of the metal fragments and the binding stoi-
chiometry, can be achieved by electrospray ionization
mass spectrometry (ESI–MS) (Merlino et al. 2017).
In this work, we describe the preparation, charac-
terization and the antiproliferative effects toward a
representative panel of cancer cell lines of five new
palladium(II) and platinum(II) complexes with differ-
ent 40-substituted terpy ligands of general formula:
[MCl(L)]BF4, where M represents Pd(II) or Pt(II) and
L represents the corresponding terpy ligand L1–L3,
(Scheme 1). L1 and L2 have been selected to increase
the solubility of desired complexes in physiological
conditions, while the use of L3 as a ligand can ensure
additional p–p stacking interactions and the alkylating
potential after coordination to the metal center. Also,
their interactions with model proteins (i.e. HEWL, cyt
c and RNase A) has been investigated through ESI–
MS analysis following a well-established experimen-
tal protocol (Merlino et al. 2017).
Materials and methods
PdCl2, K2[PtCl4] and NaBF4 were purchased from
Sigma-Aldrich, while the solvents were obtained from
different commercial sources and used as received.
Ligands were prepared following synthetic procedures
reported in literature (Sampath et al. 1999; Andres
et al. 2003; Anthonysamy et al. 2008). RNase A (from
bovine pancreas R5500), cytochrome c (from equine
Fig. 1 Chemical structure of some representative literature
examples of metal complexes with terpy ligands having
promising cytotoxic activity: a [Pd(sac)(terpy)](sac)4H2O
(Ulukaya et al. 2011), b [PtClL1]Cl, (L1 = 4
0-(4-
hydroxyphenyl)-2,20,60,200-terpyridine, c [PdClL2]Cl, (L2 = 40-
(4-carboxymethylphenyl)-2,20,60,200-terpyridine), d [Zn(CH3-
COO)2L3], (L3 = 4
0-(4-(2-morpholinoethoxy)phenyl)-2,20,60,
200-terpyridine, e [CuCl2L1] (Wang et al. 2013)
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heart C7752) and hen egg wite lysozyme (HEWL)
were purchased from Sigma-Aldrich and used without
further purifications. Elemental analysis (C, H, N) was
carried out with a Thermo Scientific Flash 2000 Series
CHNS/O Analyzer. NMR spectra were recorded in
DMSO-d6, on a Bruker Avance 500 MHz and all
chemical shifts are given relative to tetramethylsilane
(TMS). Signals at ca. 2.5 and 3.3 ppm correspond to
solvent (DMSO) and residual water peaks, respec-
tively. Numbering of the all protons in 1H NMR data is
presented in Fig. 2. Standard LC–MS analysis was
performed on an Agilent 1100 series HPLC equipped
with a quaternary pump and UV–DAD detection,
directly coupled to an Agilent G1956B single quadru-
pole MS detector equipped with an ESI ionization
source. High resolution mass spectrometry (HRMS)
was performed on an Agilent 1100 series HPLC
equipped with a quaternary pump and UV–DAD
detector directly coupled to an Agilent 6220A series
Time-of-Flight MS detector, equipped with an ESI/
APCI (multimode) ionization source. IR spectra were
recorded from 4000 to 650 cm-1, on a Thermo
Scientific FT-IR spectrometer (type Nicolet 6700),
using KBr as a non-absorbing matrix.
Scheme 1 Schematic
representation of the
synthetic procedure.
Reagents and conditions:
a PdCl2 or K2[PtCl4],
CH3NO2, 24 h reflux,
b CH3CH2OCH2CH3;
c CH3OH/H2O or CH3OH/
CHCl3 or CH3OH/CHCl3/
H2O
Fig. 2 The numbering of the protons in the 1H NMR spectra of the complexes 1–5
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Synthesis and characterization
[PdCl(L1)]BF4 (1)
A mixture of PdCl2 (21.3 mg, 0.12 mmol), L1
(36.9 mg, 0.12 mmol) and NaBF4 (26.3 mg,
0.24 mmol) in nitromethane (20 mL) was stirred
under reflux for 24 h. After cooling to room temper-
ature, the reaction mixture was filtered and concen-
trated almost to dryness. After adding diethyl ether
(5 mL), the complex was precipitated and separated
by filtration. The obtained pale yellow solid was
washed with methanol and water. Yield: 28.2 mg,
41.7%. Anal. Calcd. (%) for C18H17BClF4N3O2-
Pd0.25H2O: C, 40.00; H, 3.25; N, 7.77. Found: C,
39.77; H, 2.92; N, 7.93. IR (KBr, cm-1): 3527 m,
3334 m, 3073 m, 2954 m, 2893 m, 1616 s, 1608 s,
1558 s, 1541 s, 1497 s, 1473 s, 1458 s, 1363 s,
1224 m, 1169 s, 1044 m, 891 w, 840 w, 774 m. 1H
NMR (ppm, DMSO-d6, 500 MHz, 25 C): d 2.00
(quin, 2H, H8), 3.64 (m, 2H, H9), 4.43 (t, 2H, H7),
4.74 (br. s., 1H, –OH), 7.80–7.91 (m, 2H, H5 and
H500), 8.22 (s, 2H, H30 and H50), 8.40–8.50 (m, 2H, H4
and H400), 8.59–8.71 (m, 4H, H3, H6, H300 and H600).
HRMS [CH3CN, m/z]: 448.0035 ([M]
?).
[PdCl(L2)]BF4 (2)
This complex was synthesized as described for
complex 1, with PdCl2 (19.6 mg, 0.11 mmol), L2
(40.0 mg, 0.11 mmol) and NaBF4 (24.2 mg,
0.22 mmol). The obtained pale yellow solid was
washed with methanol/chloroform (v/v, 1/3). Yield:
26.8 mg, 41.1%. Anal. Calcd. (%) for C21H21BClF4-
N3O3Pd: C, 42.57; H, 3.57; N, 7.10. Found: C, 42.43;
H, 3.41; N, 6.69.IR (KBr, cm-1): 3337 w, 3066 w,
2948 w, 2870 w, 1732 m, 1720 m, 1608 m, 1563 m,
1481 m, 1466 m, 1366 m, 1220 m, 1175 m, 1103 s,
1085 s, 883 w, 796 m, 754 w. 1H NMR (ppm, DMSO-
d6, 500 MHz, 25 C): d 1.52 (m, 2H, H9), 1.58–1.69
(m, 2H, H10), 1.81–1.93 (m, 2H, H8), 2.29 (t, 2H,
H11), 4.38 (t, 2H, H7), 7.82–7.94 (m, 2H, H5 and
H500), 8.23 (s, 2H, H30 and H50), 8.41–8.53 (m, 2H, H4
and H400), 8.60–8.72 (m, 4H, H3, H6, H300 and H600),
12.06 (br.s., 1H, –COOH). HRMS [CH3CN, m/z]:
504.0295 ([M]?).
[PdCl(L3)]BF4 (3)
This complex was synthesized as described for
complex 1, with PdCl2 (23.3 mg, 0.13 mmol), L3
(52.3 mg, 0.13 mmol) and NaBF4 (28.5 mg,
0.26 mmol). Yield: 29.1 mg, 35.5%. Anal. Calcd.
(%) for C22H16BBrClF4N3Pd0.75H2O: C, 41.00; H,
2.74; N, 6.52. Found: C, 40.57; H, 2.59; N, 6.05. IR
(KBr, cm-1): 3107 w, 1608 s, 1559 w, 1480 s,
1434 m, 1405 m, 1283 w, 1250 m, 1068 s, 901 w,
851 s, 791 w, 753 w, 723 w, 691 w. 1H NMR (ppm,
DMSO-d6, 500 MHz, 25 C) d 4.78 (m, 2H, H11),
7.68 (m, 2H, H5 and H500), 7.74–7.89 (m, 2H, H9 and
H90), 8.09 (m, 2H, H4 and H400), 8.35-8.51 (d, 2H, H8
and H800), 8.57–8.94 (m, 6H, H3, H300, H6, H600, H30
and H50).
[PtCl(L4)]BF4 (4)
This complex was synthesized as described for
complex 1, with K2[PtCl4] (33.2 mg, 0.08 mmol),
L1 (24.6 mg, 0.08 mmol) and NaBF4 (17.6 mg,
0.16 mmol). Yield: 19.5 mg, 44.6%. Anal. Calcd.
(%) for C18H17BClF4N3O2Pt: C, 34.61; H, 2.74; N,
6.73. Found: C, 34.62; H, 2.70; N 6.86. IR (KBr,
cm-1): 3524 m, 3412 m, 3077 m, 2952 w, 2894 w,
1620 s, 1558 m, 1479 s, 1434 s, 1396 m, 1365 s,
1225 s, 1168 m, 1053 s, 890 m, 841 m, 788 s, 774 s,
754 m. 1H NMR (ppm, DMSO-d6, 500 MHz, 25 C) d
2.03 (quin, 2H, H8), 3.67 (t, 2H, H9), 4.42 (t, 2H, H7),
4.76 (br. s., 1H, –OH), 7.90 (t, 2H, H5 and H500), 8.22
(s, 2H, H30 and H50), 8.45–8.52 (m, 2H, H4 and H400),
8.62 (d, 2H, H3 and H300), 8.75 (d, 2H, H6, and H600).
HRMS [CH3CN, m/z]: 537.0660 ([M]
?).
[PtCl(L5)]BF4 (5)
This complex was synthesized as described for com-
plex 1, with K2[PtCl4] (29.4 mg, 0.07 mmol), L2
(25.4 mg, 0.07 mmol) and NaBF4 (15.4 mg,
0.14 mmol). The obtained yellow solid was washed
with methanol/chloroform and water. Yield: 18.9 mg,
39.7%. Anal. Calcd. (%) for C21H21BClF4N3O3-
Pt0.5H2O: C, 36.57; H, 3.21; N, 6.09. Found: C,
36.19; H, 2.76; N, 6.11. IR (KBr, cm-1): 3442 brs,
3082 m, 2948 m, 2613 w, 1719 m, 1619 s, 1561 m,
1480 m, 1432 m, 1399 m, 1363 m, 1224 m, 1060 m,
838 w, 787 m, 752 m, 713 w. 1H NMR (ppm, DMSO-
d6, 500 MHz, 25 C) d 1.52 (quin, 2H, H9), 1.65 (quin,
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2H, H10), 1.88 (quin, 2H, H8), 2.31 (t, 2H, H11), 4.36
(t, 2H, H7), 7.90 (t, 2H, H5 and H500), 8.22 (s, 2H, H30
and H50), 8.48 (t, 2H, H4 and H400), 8.60 (d, 2H, H3 and
H300), 8.75 (d, 2H, H6 and H60’), 12.08 (br.s., 1H, –
COOH). HRMS [CH3CN, m/z]: 593.0907 ([M]
?).
Single-crystal X-ray diffraction
For the structures of 2, 3 and 5, X-ray intensity data
were collected at 100 K, on an Agilent Supernova
Dual Source (Cu at zero) diffractometer equipped with
an Atlas CCD detector using x scans and CuKa
(k = 1.54184 A˚) for 2 or MoKa (k = 0.71073 A˚)
radiation for 3 and 5. The images were interpreted and
integrated with the program CrysAlisPro (Rigaku
Oxford Diffraction 2015). Using Olex2 (Dolomanov
et al. 2009), the structures were solved by direct
methods using the ShelXS structure solution program
and refined by full-matrix least-squares on F2 using the
ShelXL program package (Sheldrick
2008, 2015). Non-hydrogen atoms were anisotropi-
cally refined and the hydrogen atoms in the riding
mode and isotropic temperature factors fixed at 1.2
times U(eq) of the parent atoms (1.5 times for
hydroxyl groups).
Crystal data for compound 2
C21H21BClF4N3O3Pd, M = 592.07, triclinic, space
group P-1 (No. 2), a = 5.5079(5) A˚, b = 13.6989(8)
A˚, c = 16.3673(8) A˚, a = 75.216(5), b = 80.672(6),
c = 80.567(6), V = 1168.52(14) A˚3, Z = 2, T =
100 K, qcalc = 1.683 g cm
-3, l(Cu–Ka) = 8.011
mm-1, F(000) = 592, 14630 reflections measured,
4628 unique (Rint = 0.0816) which were used in all
calculations. The final R1 was 0.0528 (I[ 2r(I)) and
wR2 was 0.1423 (all data). The contribution of heavily
disordered solvent peaks (most probably from a water
molecule) was taken into using the SQUEEZE proce-
dure, implemented in the program PLATON (Spek
2009).
Crystal data for compound 3
C22H16BBrClF4N3Pd, M = 630.94, monoclinic, space
group P21/n (No. 14), a = 13.1566(5) A˚, b =
11.0090(3) A˚, c = 16.2869(5) A˚, b = 113.183(4),
V = 2168.53(14) A˚3, Z = 4, T = 100 K, qcalc =
1.933 g cm-3, l(Cu–Ka) = 2.872 mm-1, F(000) =
1232, 25,055 reflections measured, 5459 unique
(Rint = 0.0657) which were used in all calculations.
The final R1 was 0.0503 (I[ 2r(I)) and wR2 was
0.1234 (all data). During the process of crystallization
(slow diffusion of diethyl ether in the mother liquor of
the complex) nucleophilic substitution of halogen
atoms is noticed, yielding a disorder of the Cl1A and
Br1A atoms [with an occupancy of 0.592(3)], with
their positions partially occupied by Br1B and Cl1B
atoms (occupancy of 0.408(3)), respectively.
Crystal data for compound 5
C42H42BCl3F4N6O6Pt2, M = 1310.14, triclinic, space
group P-1 (No. 2), a = 13.2075(4) A˚, b = 13.9848(4)
A˚, c = 14.2143(3) A˚, a = 79.761(2), b = 74.389(2),
c = 71.023(3), V = 2379.39(12) A˚3, Z = 2, T = 100 K,
qcalc = 1.829 g cm
-3, l(Cu–Ka) = 6.108 mm-1,
F(000) = 1264, 37,298 reflections measured, 11,742
unique (Rint = 0.0649) which were used in all calcula-
tions. The final R1 was 0.0468 (I[2r(I)) and wR2 was
0.1047 (all data). The contribution of heavily disordered
solvent peaks (most probably from a diethyl ether
molecule) was taken into using the SQUEEZE procedure,
implemented in the program PLATON (Spek 2009).
In addition, ligand L2 is also characterized by X-ray
analysis and the data are presented in SI (Figs. S16 and
S17).
CCDC 1568867-1568870 contain the supplemen-
tary crystallographic data for this paper and can be
obtained free of charge via www.ccdc.cam.ac.uk/
conts/retrieving.html (or from the Cambridge Crys-
tallographic Data Centre, 12, Union Road, Cambridge
CB2 1EZ, UK; fax: ?44-1223-336033; or
deposit@ccdc.cam.ac.uk).
Spectrophotometric studies
To assess the compounds stability, spectrophotometric
studies were performed using a Varian Cary 50 Bio
UV–Vis spectrophotometer. Small amounts of freshly
prepared concentrated solutions of the five compounds
in DMSO were diluted in 20 mM ammonium acetate
buffer pH 6.8, in the presence of 1% DMSO. The
concentration of each compound in the final sample
was 10-5 M. The resulting solutions were monitored
by collection of the electronic spectra for 72 h at room
temperature in the range between 200 and 800 nm.
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Interactions with biomolecules
Metal complex–protein adducts were prepared incu-
bating for 72 h each protein (Horse heart cytochrome
c, ribonuclease A from bovine pancreas and HEWL)
with an excess of the complex (final protein concen-
tration 10-4 M, protein to metal ratio 3:1) in 20 mM
ammonium acetate buffer pH 6.8, in the presence of
30% DMSO at 37 C. Electrospray ionization mass
spectrometry (ESI–MS) spectra were recorded after a
20-fold dilution of the metal complex-protein sample
with water. Samples were introduced at 5 lL/min flow
rate in an Orbitrap high-resolution mass spectrometer
(Thermo, San Jose, CA, USA), equipped with a
conventional ESI source. The working conditions
were the following: spray voltage 3.1 kV, capillary
voltage 45 V, capillary temperature 220 C, tube lens
voltage 230 V. The sheath and the auxiliary gases
were set, respectively, at 17 (arbitrary units) and 1
(arbitrary units). For acquisition, Xcalibur 2.0. soft-
ware (Thermo) was used and monoisotopic and
average deconvoluted masses were obtained by using
the integrated—Xtract tool. For spectrum acquisition,
a nominal resolution (at m/z 400) of 100,000 was used.
Cellular studies
Cell cultures
A549 and HDF cell lines were cultured in DMEM
High glucose (Euroclone; Milan, Italy) supplemented
with 4 mM L-Glut, 10% fetal bovine serum (FBS)
(Euroclone EU Approved; Euroclone; Milan, Italy)
(complete medium). HCT-116, and IGROV-1 were
cultured in RPMI 1640 (Euroclone; Milan, Italy)
supplemented with 2 mM L-Glut, with 10% Fetal
Bovine Serum (FBS) (Euroclone Defined; Euroclone;
Milan, Italy) (complete medium). HCT116 cells were
kindly provided by Dr R. Falcioni (Regina Elena
Cancer Institute, Roma). Cells were cultured at 37 C
in a humidified atmosphere in 5% CO2 in air.
Pharmacology experiments
Cells were seeded at 1 9 104/well in 96-well plates
(Costar Corning) in complete medium and incubated
for 24 h before drug addition. Each compound was
used, after dissolving in DMSO, in a concentration
range of 0–100 lM. After 24 h, viable cells,
determined by a Trypan Blue exclusion test, were
counted in triplicate using a haemocytometer. Each
experimental point represents the mean of a single
experiment carried out in triplicate. The effect of
DMSO was subtracted from the effect of each
compound in each experiment performed.
Trypan blue assay
Cells viability was assessed by a Trypan Blue
exclusion assay. Briefly, 10 lL of 0.4% Trypan Blue
solution (Fluka) was added to 10 lL cell suspensions
in culture medium. The suspension was gently mixed
and transferred to a haemocytometer. Viable and dead
cells were identified and counted under a light
microscope. Blue cells failing to exclude the dyes
were considered nonviable, and transparent cells were
considered viable. The number of viable cells was
counted and the IC50 value (i.e., the dose that caused a
decrease in cell proliferation over control of 50%) was
calculated by fitting the data points with a sigmoidal
curve using Calcusyn software (Biosoft, Cambridge,
UK).
Results and discussion
Synthesis and chemical characterization
The ligands L1–L3 were prepared as previously
reported (Sampath et al. 1999; Andres et al. 2003;
Anthonysamy et al. 2008). Complexes 1–5 were
prepared by the reaction of PdCl2 or K2[PdCl4] with
the 40-substituted terpy ligands (L1–L3) in nitro-
methane. All complexes were isolated from the
reaction mixture as precipitates after adding diethyl
ether, in the form of monocationic complexes, with
tetrafluoroborate as counteranion (Scheme 1). The
complexes were partially soluble in DMSO and
chloroform and they showed good solubility and
stability in ammonium-acetate buffer (pH 6.8–7.0;
Fig. S1).
All the complexes were characterized by elemental
analysis, UV–Vis, IR and 1H NMR spectroscopy,
ESI–MS confirming their structure. Single-crystal
X-ray diffraction was performed for 2, 3 and 5.
The 1H NMR spectra of the ligands (Fig. S2–S4)
and corresponding complexes (Fig. S5–S9) were
recorded in DMSO-d6. The signals of aliphatic alkyl
123
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moiety of the 40-terpy ligands are found in the range
from 1.52 to 4.78 ppm. Characteristic signals at 4.74
and 4.76 ppm for complexes 1 and 4, respectively, are
assigned to the proton from the OH group of ligand L1.
The spectrum of the free ligand shows similar signals
for OH proton, indicating that this group is not
involved in coordination to the metal center. Likewise,
for both complexes, 2 and 5, the protons from the
carboxylic group are detected around 12 ppm, while
signals of the aromatic protons in the complexes are
detected in the region typical for the terpy ligand, at
expected chemical shifts.
Solution behavior
UV–Vis spectral profiles of all these complexes,
remain substantially unaltered in ammonium acetate
buffer, also after 72 h of incubation at room temper-
ature. Specifically, UV–Vis spectra of compounds 1
and 2 show three peaks approximately at 280, 330, and
350 nm (Fig. S1 A and B), while compound 3 and 4
display a broad band around 290 nm, and 275 nm,
respectively (Fig. S1 C and D). Finally, the spectrum
of compound 5 shows a main peak around 280 nm
with shoulders in the range between 300 and 350 nm.
Overall, the compounds manifested an appreciable
stability; only a slight and progressive decrease in the
intensity of the absorption was detected, most prob-
ably due to slight precipitation of the complexes. Also,
the conserved spectral profiles, imply that the presence
of DMSO does not affect the stability and the
complexes do not undergo significant structural
changes (Fig. S1).
Single-crystal X-ray structural analysis
Compound 2 crystallized in the triclinic centro-
symmetric space group P-1, with the asymmetric unit
consisting of one [PdCl(L2)]?complex cation and one
BF4
- counterion. The Pd(II) atom is four-coordinated
by the nitrogen atoms of the tridentate chelating L2
ligand and a chloride ion, showing a square-planar
geometry (Fig. 3). The dihedral angle between planes
through the respective outer pyridine rings N2/C6–
C10 and N3/C11–C15 is only 1.8(3), and the dihedral
angles between the outer rings and central pyridine
ring N1/C1–C5 are 0.9(3) and 1.9(3), respectively.
The Pd–N bond distance to the central nitrogen atom
[Pd1–N1 = 1.966(5) A˚] is slightly shorter than to the
two outer nitrogen atoms [Pd1–N2 = 2.007(5) A˚ and
Pd1–N3 = 2.016(6) A˚]. The bond angles [N2–Pd1–N1
(80.98(19)], [N3–Pd1–N1 (80.88(19)] and [N2–
Pd1–N3 (161.9(2)] deviate from ideal values of 90
and 180, respectively, because of the geometric
constraints imposed by the L2 ligand.
The carboxypentoxy chain is found completely
staggered, and is almost planar with respect to the
terpyridine ring system (C2–C3–O1–C16 torsion
angle of - 175.0(5)). The largest deviation in torsion
angle from the ideal value of 180 in the carboxypen-
toxy chain is - 172.6(5) for C16–C17–C18–C19.
In the crystal packing, classic hydrogen bonds are
observed between the carboxyl group and a BF4
-
fluorine atom [O2(–H2)F2 = 2.701(6) A˚].
Multiple p–p stacking interactions are observed
between the pyridine rings with centroid–centroid
distances in the range of 3.948(3)–5.508(4) A˚, conse-
quently building up columns of terpyridine ring
systems along the [100] direction (Fig. S10). Further-
more, Y–Xp interactions are observed between
Pd1–Cl1 and pyridine rings N2/C6–C10 and N3/
C11–C15 (Y(–X)centroid = 3.745(3) A˚ and
3.495(3) A˚, respectively), and between C21 and O3
and pyridine ring N2/C6–C10 [3.472(5) A˚]. In fact,
layers containing terpyridine and carboxypentoxy
moieties are observed parallel with the (001) plane
(Fig. S11).
Compound 3 crystallized in the triclinic space
group P-1, with the asymmetric unit consisting of one
[PdCl(L3)]? complex cationand one BF4
- counterion.
Analogous to 2, the Pd(II) atom is four-coordinated by
the nitrogen atoms of the tridentate chelating L3
ligand and a chloride ion, showing a square-planar
geometry (Fig. 4). Here, the terpyridine ring system is
slightly less planar than in 2, i.e. the dihedral angle
between planes through the respective outer pyridine
rings N2/C6–C10 and N3/C11–C15 is 5.5(2), and the
dihedral angles between the outer rings and central
pyridine ring N1/C1–C5 are 3.1(2) and 6.9(2),
respectively. Analogous to 2, the Pd–N bond distance
to the central nitrogen atom [Pd1–N1 = 1.928(4) A˚] is
slightly shorter than to the two outer nitrogen atoms
[Pd1–N2 = 2.031(4) A˚ and Pd1–N3 = 2.037(3) A˚].
The bond angles N2–Pd1–N1 [80.79(18)], N3–Pd1–
N1 [81.35(17)] and N2–Pd1–N3 [162.14(17)] devi-
ate from ideal values because of the geometric
constraints imposed by the L3 ligand. The bro-
momethyl benzene ring is torsioned with respect to
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the central pyridine ring (dihedral angle between
planes through the respective outer rings of 37.9(2)).
The bromomethyl group itself is also torsioned with
respect to the benzene ring (C18–C19–C22–Br1
torsion angle of - 120.4(5)), showing a potential
hydrogen bond, formed between the pyridine C7–H7
and the bromine atom (C7(–H7)Br1 = 3.754(6) A˚).
Multiple p–p stacking interactions are observed
between the pyridine and benzene rings with centroid–
centroid distances in the range of 3.686(3)–5.892(3)
A˚. Furthermore, Y–Xp interactions are observed
between C22-Br1, Pd1–Cl1 and pyridine rings N1/
C1–C5 (Y(–X)centroid = 3.416(6) A˚ and 3.36(3) A˚,
respectively), as such a herringbone pattern is
observed in the packing along the [100] direction
(Fig. S12). Compound 5 crystallized in the triclinic
space group P-1, with two[PtCl(L2)]? complex
cations, one BF4
-and one Cl- counterions in the
asymmetric unit.
Analogous to 2 and 3, the Pt(II) atoms in both
molecules are four-coordinated by the nitrogen atoms
of the tridentate chelating L2 ligand and a chloride ion,
showing a square-planar geometry (Fig. 5). The
dihedral angle between planes through the respective
outer pyridine rings of both molecules is 1.6(3) and
1.7(4), respectively, while the dihedral angles
between the outer rings and central pyridine ring are
4.1(3) and 3.0(3) for the first molecule and 2.5(4)
and 1.3(3) for the second molecule. The Pt–N bond
distances to the central nitrogen atom (Pt1–
N1 = 1.932(5) A˚; Pt2–N4 = 1.938(6) A˚) are again
slightly shorter than to the two outer nitrogen atoms
(Pt1–N2 = 2.021(5) A˚, Pt1–N3 = 2.020(4) A˚; Pt2–
N5 = 2.009(6) A˚, Pt2–N6 = 2.015(6) A˚).
Analogous to the former structures of 2 and 3, the
bond angles N2–Pt1–N1 (80.8(2)), N3–Pt1–N1
(81.2(2)) and N2–Pt1–N3 (161.9(2)) for the first
molecule and N5–Pt2–N4 (81.0(2)), N6–Pt2–N4
(81.3(2)) and N5–Pt2–N6 (162.3(3)) for the second
molecule deviate again from ideal values. Compared
to 2, the carboxypentoxy chains of both molecules are
not planar with respect to their terpyridine ring
systems, mainly because of the O1–C16–C17–C18
torsion angle (60.8(7)) and O4–C37–C38–C39
Fig. 4 Asymmetric unit of 3, showing thermal displacement
ellipsoids at the 50% probability level and atom-labeling
scheme of the non-hydrogen atoms
Fig. 3 Asymmetric unit of
2, showing thermal
displacement ellipsoids at
the 50% probability level
and atom-labeling
scheme of the non-hydrogen
atoms
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torsion angle (62.2(8)), for the first and second
molecule, respectively. Hydrogen bonds are observed
between the carboxyl groups of both molecules and
the Cl- chloride anion (O3(–H3)Cl3 = 3.010(7) A˚;
O6(–H6)Cl3 = 2.992(5) A˚). Multiple p–p stacking
interactions are observed between the pyridine rings of
both molecules with centroid–centroid distances in the
range of 3.623(4)–5.755(4) A˚, consequently building
up columns of terpyridine ring systems along the [010]
direction (Fig. S13).
Furthermore, Y–Xp interactions are observed
between Pt1-Cl1, Pt2-Cl2 and central pyridine rings
N1/C1–C5, N4/C22–C26, respectively (Y(–X)cen-
troid = 3.629(3)A˚ and 3.639(3)A˚, respectively).
Reactions with model proteins
The interactions of the five compounds with the
selected model proteins i.e. HEWL, cyt c and RNase A
were subsequently monitored through ESI–MS anal-
ysis. ESI–MS spectra, turned out particularly infor-
mative in determining the final metal to protein
stoichiometry and the nature of protein bound metallic
fragments. The results are summarized in Fig. 6
(interaction with RNase A) and in the SI (interaction
with HEWL and cyt c). It is evident that none of the
compounds showed reactivity towards HEWL
(Fig. S14). A limited reactivity of palladium-based
compounds is observed by inspection of ESI–MS
spectra. Only in the case of RNase A incubated with
compounds 2 and 3, small amounts of metal–protein
adducts have been detected. The metallic fragments
bound to RNase A consist of the [Pd(II)L]2? moiety
for compound 2 (Fig. 6b) and with L losing the
bromide for compound 3 (Fig. 6c). In contrast, the
platinum-based complexes (compound 4 and 5)
showed an evident reactivity toward RNase A and a
modest reactivity toward cyt c. In the latter case only
mono- and bi-metalated derivatives are formed
(Fig. S15), while in the case of RNase A also tri-
and tetra-metalated derivatives have been detected
(Fig. 6). Taking in account that hydrolysis of the Pd-
Cl bond plays an important role in the process of the
reaction of this type of complexes towards biomole-
cules, high stability of this bond in the ammonium-
acetate buffer could be a reason for the lower
reactivity of the palladium complexes in reaction with
the proteins (Shoukry et al. 1998; Wimmer and
Wimmer 1998).
Antiproliferative properties
The antiproliferative properties of compounds 1–5
were assessed against a small panel of human cancer
cell lines (A549, HCT116 and IGROV-1) as well as
against one normal cell line (HDF). Table 1 summa-
rizes the IC50 values for the five compounds,
cFig. 6 LTQ Orbitrap ESI mass spectra of compound 1 (a), 2
(b) 3 (c), 4 (d) and 5 (e), dissolved in 20 mM ammonium
acetate, pH 6.8 and 30% DMSO in the presence of RNase A after
72 h of incubation at 37 C. The protein concentration was 10-4
M (with a metal complex to protein molar ratio of 3:1)
Fig. 5 Asymmetric unit of
5, showing thermal
displacement ellipsoids at
the 50% probability level
and atom-labeling
scheme of the non-hydrogen
atoms
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Fig. 6 continued
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determined according to the method described in the
experimental section.
It is evident that palladium-based compounds (1, 2
and 3) and the platinum compound 5 showed similar
cytotoxicity over all the cancer cell lines as well as on
the normal one, while the platinum-based compound 4
exhibited lower IC50 values for all the tumor cell lines
compared to normal cells (Table 1). Good selectivity
of 4 towards cancer cell in comparison with normal
cell may be the consequence of a different cellular
uptake. We stress that human cancer cell lines (A549,
IGROV1 and HCT-116) were (highly)sensitive to the
treatment with 1–5 in the comparison with literature
data related to cisplatin (IC50 = 42 lM for A549,
IC50 = 21 lM for IGROV1 and IC50 = 23 lM for
HCT-116) (Seliman et al. 2018; Serova et al. 2005;
Cirri et al. 2017).
Conclusions
The syntheses of five novel complexes of palla-
dium(II) and platinum(II) with 2,20:60,200-terpyridine
(terpy) derivatives modified at the 40 position have
Table 1 A549, IGROV-1, HCT-116 and HDF cell lines were exposed to IC50 concentrations of selected drugs for 24 h
IC50 (lM) A549 IGROV1 HCT-116 HDF
1 5.37 ± 0.70 7.32 ± 0.41 8.00 ± 0.33 15.43 ± 1.00
2 14.00 ± 1.31 12.50 ± 1.24 18.09 ± 1.20 17.03 ± 1.29
3 4.16 ± 0.31 4.40 ± 0.49 10.94 ± 0.72 7.79 ± 0.39
4 8.96 ± 0.92 6.90 ± 0.71 6.39 ± 0.49 103.30 ± 16.27
5 32.37 ± 2.36 16.16 ± 1.73 21.42 ± 1.39 36.42 ± 1.90
Cell viability was evaluated via a Trypan Blue exclusion assay. Means and SDs are relative to one experiment mounted in triplicate
Fig. 6 continued
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been described. The compounds were characterized by
UV/Vis, IR, NMR spectroscopy, mass spectrometry,
elemental and X-ray analysis. Based on the UV–Vis
spectral profiles obtained for the investigated com-
plexes it appears clear as all complexes show an
appreciable stability in ammonium acetate buffer
during analysis at 72 h at room temperature. All
investigated complexes were tested for in vitro
antiproliferative activity against a panel of human
cell lines (A549, HCT116 and IGROV-1) and one
normal cell line (HDF) as control. Among the
examined complexes, compound 4 exhibited the
highest activity (IC50(A549) = 8.96 ± 0.92 lM,
IC50(IGROV1) = 6.90 ± 0.71 lM and IC50(HCT-
116) = 6.39 ± 0.49 lM) and good selectivity in
comparison with normal cells (IC50(-
HDF) = 103.30 ± 16.27 lM), while the other com-
plexes showed similar cytotoxicity on the tumor and
normal cell lines. The protein binding experiments
suggest that the platinum compounds (4 and 5) are able
to bind to the model protein RNase A producing
mono-, bi-, tri- and tetra-metalated derivatives (RNase
A ? [Pt(II)L]2? ? 2SO4
2-, RNase A ?
2[Pt(II)L]2? ? 2SO4
2-, RNase A ? 3[Pt(II)L]2?-
? 2SO4
2-, RNase A ? 4[Pt(II)L]2? ? 2SO4
2-),
while their modest reactivity towards cyt c resulted
in the formation of mono and bi-metalated adducts
(cyt c ? [Pt(II)L]2? and cyt c ? 2[Pt(II)L]2?). The
limited reactivity of the palladium complexes (1, 2 and
3) towards the selected proteins indicates a potentially
different mode of action of the Pd complexes in
comparison with Pt complexes (4 and 5). Overall, the
obtained results support the hypothesis that terpyridine
Pt/Pd complexes possess interesting biological activ-
ity and are worthy of further, more detailed investi-
gations, especially with the goal of determining their
precise mode of action.
Acknowledgements A.S., R.V.D. and K.V.H. thank the
Erasmus Mundus Basileus V project. T.M. thanks AIRC-FIRC
(Fondazione Italiana per la Ricerca sul Cancro, 3-years
Fellowship for Italy Project Code: 18044) and University of
Pisa (PRA_2017_25) for financial support. CIRCMSB, Dr.
Serena Pillozzi and Prof. Annarosa Arcangeli are also
acknowledged. CISM (University of Florence) is acknowledge
for recording ESI–MS spectra. K.V.H. and R.V.D. thank the
Hercules Foundation (Project AUGE/11/029 ‘‘3D-SPACE: 3D
Structural Platform Aiming for Chemical Excellence’’) for
funding. K.V.H. thanks the Research Foundation—Flanders
(FWO) (Project 1.5.216.15N) for financial support.
References
Andres PR, Lunkwitz R, Pabst GR, Bohn K, Woutres D, Sch-
matloch S, Schubert US (2003) New 40 functionalized
2,20:60,20 0-terpyridines for applications in macromolecular
chemistry and nanoscience. Eur J Org Chem 19:3769–3776
Anthonysamy A, Balasubramanian S, Vellasamy V, Mathiva-
nan N (2008) Synthesis, characterization and electro-
chemistry of 40-functionalized 2,20:60,200-terpyridine
ruthenium(II) complexes and their biological activity.
Dalton Trans 16:2136–2143
Chu W, Wang Y, Liu S, Yang X, Wang S, Li S, Zhou G, Qin X,
Zhou C, Zhang J (2013) Synthesis, cytotoxicity and DNA-
binding properties of Pd(II), Cu(II) and Zn(II) complexes
with 40-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,20:60,20’-
terpyridine. Bioorg Med Chem Lett 23:5187–5191
Cirri D, Pillozzi S, Gabbiani C, Tricomi J, Bartoli G, Stefanini
M, Michelucci E, Arcangeli A, Messori L, Marzo T (2017)
PtI2(DACH), the iodido analogue of oxaliplatin as a can-
didate for colorectal cancer treatment: chemical and bio-
logical features. Dalton Trans 46:3311–3317
Cutillas N, Yellol GS, Haro C, Vicente C, Rodrı´gez V, Ruiz J
(2013) Anticancer cyclometalated complexes of platinum
group metals and gold. Coordin Chem Rev 257:2784–2797
Dolomanov OV, Bourhis LJ, Gildea RJ, Howard JAK, Pusch-
mann H (2009) OLEX2: a complete structure solution,
refinement and analysis program. J Appl Crystallogr
42:339–341
Eryazici I, Moorefield CN, Newkome GR (2008) Square-planar
Pd(II), Pt(II), and Au(III) terpyridine complexes: their
syntheses, physical properties, supramolecular constructs,
and biomedical activities. Chem Rev 108(6):1834–1895
Gabbiani C, Casini A, Kelter G, Cocco F, Cinellu MA, Fiebig
HH, Messori L (2011) Mechanistic studies on two dinu-
clear organogold(III) compounds showing appreciable
antiproliferative properties and a high redox stability.
Metallomics 3:1318–1323
Gabbiani C, Massai L, Scaletti F, Michelucci E, Maiore L,
Agostina Cinellu M, Messori L (2012) Protein metalation
by metal-based drugs: reactions of cytotoxic gold com-
pounds with cytochrome c and lysozyme. J Biol Inorg
Chem 17:1293–1302
Gao EJ, Wang L, Zhu MC, Liu L, Zhang WZ (2010) Synthesis,
characterization, interaction with DNA and cytotoxicity
in vitro of the complexes [M(dmphen)(CO3)]H2O [M =
Pt(II), Pd(II)]. Eur J Med Chem 45:311–316
Gasser G, Ott I, Metzler-Nolte N (2011) Organometallic anti-
cancer compounds. J Med Chem 54(1):3–25
Hollis LS, Lippard SJ (1983) Aqueous chemistry of (2,20,200-
terpyridine)gold(III). Preparation and structures of
chloro(2,20,200-terpyridine)gold dichloride trihydrate
([Au(terpy)Cl]Cl2.3H2O) and the mixed valence gold(I)-
gold(III) salt bis[chloro(2,20,200-terpyridine)gold]
tris(dichloroaurate) tetrachloroaurate ([Au(terpy)Cl]2[-
AuCl2]3[AuCl4]). J Am Chem Soc 105:4293–4299
Indumathy R, Radhika S, Kanthimathi M, Weyhermuller T,
Unni Nair B (2007) Cobalt complexes of terpyridine
ligand: crystal structure and photocleavage of DNA.
J Inorg Biochem 101(3):434–443
123
46 Biometals (2019) 32:33–47
Jakupec M, Galanski M, Arion VB, Hartinger CG, Keppler BK
(2008) Antitumour metal compounds: more than theme
and variations. Dalton Trans 2:183–194
Jamieson ER, Lippard SJ (1999) Structure, recognition, and
processing of cisplatin-DNA Adducts. Chem Rev
99(9):2467–2498
Jennette KW, Gill JT, Sadownick JA, Lippard SJ (1976)
Metallointercalation reagents. Synthesis, characterization,
and structural properties of thiolato(2,20,20’-terpyridine)-
platinum(II) complexes. J Am Chem Soc
98(20):6159–6168
Kumar A, Chinta JP, Ajay AK, Bhat MK, Rao CP (2011)
Synthesis, characterization, plasmid cleavage and cyto-
toxicity of cancer cells by a copper(II) complex of
anthracenyl-terpyridine. Dalton Trans 40:10865–10872
Lippard SJ (1978) Platinum complexes: probes of polynu-
cleotide structure and antitumor drugs. Acc Chem Res
11(5):211–217
Ma Z, Cao YQ, Li QS, Silva MFCG, Silva JJRF, Pambeiro AJL
(2010) Synthesis, characterization, solid-state photo-lu-
minescence and anti-tumor activity of zinc(II) 40-phenyl-
terpyridine compounds. J Inorg Biochem 104:704–711
Merlino A, Marzo T, Messori L (2017) Protein metalation by
anticancer metallodrugs: a joint ESI MS and XRD inves-
tigative strategy. Chem Eur J 23:6942–6947
Muggia F (2009) Platinum compounds 30 years after the
introduction of cisplatin: implications for the treatment of
ovarian cancer. Gynecol Oncol 112(1):275–281
Naseri Z, Kharat AN, Banavand A, Bakhoda A, Foroutannejad S
(2012) First row transition metal complexes of thienyl
substituted terpyridine: structural, photophysical and bio-
logical studies. Polyhedron 33:396–403
Patel MN, Joshi HN, Patel CR (2012) Copper(II) complexes
with norfloxacin and neutral terpyridines: cytotoxic,
antibacterial, superoxide dismutase and DNA-interaction
approach. Polyhedron 40:159–167
Quiroga AG (2012) Understanding trans platinum complexes as
potential antitumor drugs beyond targeting DNA. J Inorg
Biochem 114:106–112
Rigaku Oxford Diffraction (2015) CrysAlis Pro. Rigaku Oxford
Diffraction, Yarnton
Rocha FV, Barra CV, Netto AVG, Mauro AE, Carlos IZ, Frema
RCG, Anasis SR, Quilles MB, Stevanto A, Rocha MC
(2010) 3,5-Dimethyl-1-thiocarbamoylpyrazole and its
Pd(II) complexes: synthesis, spectral studies and antitumor
activity. Eur J Med Chem 45:1698–1702
Sampath US, Putnam WC, Osiek TA, Touami S, Xie J, Cohen
D, Cagnolini A, Droege P, Klug D, Barnes CL, Modak A,
Bashkin JK, Jurisson S (1999) Terpyridyl derivatives as
bifunctional chelates: synthesis and crystal structures of 40-
[2-(1,3-dioxolan-2-yl)ethylsulfanyl]-2,20-60,200-terpyridine
and chloro(40-methylsulfanyl-2,20-60,200-terpyridine)-
gold(III) bis(trifluoromethanesulfonate). Dalton Trans
12:2049–2058
Sauvage JP, Collin JP, Chambron JC, Guillerez S, Coudret C,
Balzani V, Berigelletti F, De Cola L, Flamigni L (1994)
Ruthenium(II) and osmium(II) bis(terpyridine) complexes
in covalently-linked multicomponent systems: synthesis,
electrochemical behavior, absorption spectra, and
photochemical and photophysical properties. Chem Rev
94:993–1019
Seliman AAA, Altaf M, Onawole AT, Al-Saadi A, Ahmad S,
Alhoshani A, Bhatia G, Isab AA (2018) Synthesis, X-ray
structure and cytotoxicity evaluation of carbene-based
gold(I) complexes of selenones. Inorganica Chim Acta
476:46–53
Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen
AK, Laar ESV, Waters SJ, Cvitkovic E, Raymond E (2005)
Characterizations of irofulven cytotoxicity in combination
with cisplatin and oxaliplatin in human colon, breast, and
ovarian cancer cells. Cancer Chemother Pharmacol
57:491–499
Sheldrick GM (2008) A short history of SHELX. Acta Crys-
tallogr A 64:112–122
Sheldrick GM (2015) Crystal structure refinement with
SHELXL. Acta Crystallogr C 71:3–8
Shi PF, Jiang Q, Zhao YM, Zhang YM, Lin J, Lin LP, Ding J,
Guo ZJ (2006) DNA binding properties of novel cytotoxic
gold(III) complexes of terpyridine ligands: the impact of
steric and electrostatic effects. J Biol Inorg Chem
11:745–752
Shoukry A, Rau T, Shoukry M, van Eldik R (1998) Kinetics and
mechanisms of the ligand substitution reactions of
bis(amine)(cyclobutane-1,1-dicarboxylato)palladium(II).
Dalton Trans 18:3105–3112
Spek AL (2009) Structure validation in chemical crystallogra-
phy. Acta Crystallogr D 65:148–155
Todd RC, Lippard SJ (2010) Structure of duplex DNA con-
taining the cisplatin 1,2-{Pt(NH3)2}
2?-d(GpG) cross-link
at 1.77 A˚ resolution. J Inorg Biochem 104:902–908
Trevisan A, Marzano C, Cristofori P, Borella Venturini M,
Giovagnini L, Fregona D (2002) Synthesis of a palla-
dium(II)-dithiocarbamate complex: biological assay and
nephrotoxicity in rats. Arch Toxicol 76:262–268
Ulukaya E, Ari F, Dimas K, Ikitimur EI, Guney E, Yilmaz VT
(2011) Anti-cancer activity of a novel palladium(II) com-
plex on human breast cancer cells in vitro and in vivo. Eur J
Med Chem 46:4957–4963
Wang D, Lippard SJ (2005) Cellular processing of platinum
anticancer drugs. Nat Rev Drug Discov 4:307–320
Wang S, Chu W, Wang Y, Liu S, Zhang J, Li S, Wie H, Zhou G,
Qin X (2013) Synthesis, characterization and cytotoxicity
of Pt(II), Pd(II), Cu(II) and Zn(II) complexes with 40-sub-
stituted terpyridine. Appl Organomet Chem 27:373–379
Wimmer FL, Wimmer S (1998) On the stability of palladium(II)
aqua complexes with 2,20-bipyridyl and 1,10-phenanthro-
line. Inorganica Chim Acta 149:1–3
Yeung CT, Lee WS, Tsang CS, Yiu SM, Wong WT, Kwong HL
(2010) Chiral C1-symmetric 2,2
0:60,20’-terpyridine ligands:
synthesis, characterization, complexation with copper(II),
rhodium(III) and ruthenium(II) ions and use of the com-
plexes in catalytic cyclopropanation of styrene. Polyhedron
29:1497–1507
Zhang QL, Liu JG, Xu H, Li H, Liu JZ, Zhou H, Qu LH, Ji LN
(2001) Synthesis, characterization and DNA-binding
studies of cobalt(III)polypyridyl complexes. Polyhedron
20:3049–3055
123
Biometals (2019) 32:33–47 47
